menu search

LMLLF / PharmaDrug initiates manufacturing of PD-001 for clinical programs in rare cancers and COVID-19

PharmaDrug initiates manufacturing of PD-001 for clinical programs in rare cancers and COVID-19
PharmaDrug Inc announced that it has initiated the manufacturing of PD-001, a patented enteric-coated oral formulation of cepharanthine, for non-clinical and clinical studies in cancer and infectious diseases. The company said that this comes after its recent announcements of the successful completion of its pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA) regarding the proposed development of PD-001 for the treatment of mild to moderate coronavirus (COVID-19) and positive pre-clinical study results with PD-001 for esophageal cancer and other undisclosed cancers. Read More
Posted: Jan 26 2022, 09:34
Author Name: Proactive Investors
Views: 103195

LMLLF News  

PharmaDrug to acquire Securedose Synthetics in all-stock deal

By Proactive Investors
October 27, 2023

PharmaDrug to acquire Securedose Synthetics in all-stock deal

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) announced that it will acquire all of the issued and outstanding shares of Securedose Synthetics Inc, a privat more_horizontal

PharmaDrug to consolidate shares, appoints new CFO

By Proactive Investors
October 23, 2023

PharmaDrug to consolidate shares, appoints new CFO

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) (PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF), PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF)). said it will consolidate its more_horizontal

PharmaDrug consolidates shares, appoints new CFO

By Proactive Investors
October 23, 2023

PharmaDrug consolidates shares, appoints new CFO

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF). said it will consolidate its common shares on a seven-to-one basis from October 24, 2023, and that the record more_horizontal

PharmaDrug advances investigational cancer therapeutic PD-001 toward in human safety trials

By Proactive Investors
September 14, 2023

PharmaDrug advances investigational cancer therapeutic PD-001 toward in human safety trials

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) said it continues to advance its patented reformulated enteric-coated version of orally bioavailable cepharanth more_horizontal

PharmaDrug appoints Robert Steen as CEO and chairman

By Proactive Investors
September 6, 2023

PharmaDrug appoints Robert Steen as CEO and chairman

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) announced it has appointed seasoned entrepreneur Robert Steen as its new CEO and chairman of the Board of Direc more_horizontal

PharmaDrug announces $300,000 strategic investment in Sairiyo subsidiary by PharmaTher

By Proactive Investors
July 18, 2023

PharmaDrug announces $300,000 strategic investment in Sairiyo subsidiary by PharmaTher

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) has announced a $300,000 investment in its Sairiyo Therapeutics biotech subsidiary by PharmaTher Inc, a wholly- more_horizontal

PharmaDrug brings on veteran consultant to maximize cepharanthine and DMT program value

By Proactive Investors
May 23, 2023

PharmaDrug brings on veteran consultant to maximize cepharanthine and DMT program value

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) announced the addition of David Posner to its advisory committee and as a consultant with a mandate for strateg more_horizontal

PharmaDrug partners with PharmaTher to develop DMT transdermal patch technology

By Proactive Investors
February 22, 2023

PharmaDrug partners with PharmaTher to develop DMT transdermal patch technology

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) announced that it has entered into a research collaboration agreement with PharmaTher Holdings Ltd to evaluate more_horizontal


Search within

Pages Search Results: